Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Bernard Zinman

Showing results (51-60 of 391) with videos related to

Pageof 40
Sort By:
Journal of General Internal Medicine|March 16, 2007
Deficiencies in the quality of diabetes care: comparing specialist with generalist care misses the pointBaiju R Shah, Janet E Hux, Andreas Laupacis, et al.
Diabetes Care|December 17, 2009
Effect of Rosiglitazone and Ramipril on {beta}-cell function in people with impaired glucose tolerance or impaired fasting glucose: the DREAM trialAnthony J Hanley, Bernard Zinman, Patrick Sheridan, et al.
Diabetes Care|June 29, 2011
Changes over time in glycemic control, insulin sensitivity, and beta-cell function in response to low-dose metformin and thiazolidinedione combination therapy in patients with impaired glucose toleranceRavi Retnakaran, Ying Qi, Stewart B Harris, et al.
Diabetes Care|November 25, 2003
Adiponectin in a native Canadian population experiencing rapid epidemiological transitionAnthony J G Hanley, Philip W Connelly, Stewart B Harris, et al.
The Journal of Clinical Endocrinology and Metabolism|August 1, 2015
The Impact of Chronic Liraglutide Therapy on Glucagon Secretion in Type 2 Diabetes: Insight From the LIBRA TrialCaroline K Kramer, Bernard Zinman, Haysook Choi, et al.
Diabetes, Obesity & Metabolism|February 10, 2017
Chronic liraglutide therapy induces an enhanced endogenous glucagon-like peptide-1 secretory response in early type 2 diabetesCaroline K Kramer, Bernard Zinman, Haysook Choi, et al.
The Journal of Clinical Endocrinology and Metabolism|May 5, 2017
Impact of the Glucagon Assay When Assessing the Effect of Chronic Liraglutide Therapy on Glucagon SecretionCaroline K Kramer, Bernard Zinman, Haysook Choi, et al.
Diabetes, Obesity & Metabolism|September 18, 2025
Empagliflozin for the preservation of beta-cell function in women with recent gestational diabetes: A randomized placebo-controlled trialShamini Murugavel, Ravi Retnakaran, Denice S Feig, et al.
Endocrine Practice : Official Journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists|June 7, 2019
INTERMITTENT INTENSIVE INSULIN THERAPY FOR TYPE 2 DIABETES: EFFECTS ON HYPOGLYCEMIA, WEIGHT GAIN, AND QUALITY OF LIFE OVER 2 YEARSAlexandra Emery, Chang Ye, Haysook Choi, et al.
The American Journal of Medicine|July 9, 2010
Confronting the type 2 diabetes epidemic: the emerging role of incretin-based therapiesVivian A Fonseca, Bernard Zinman, Michael A Nauck, et al.
Pageof 40

Showing results (51-60 of 391) with videos related to

Sort By:
Pageof 40
Journal of General Internal Medicine|March 16, 2007
Deficiencies in the quality of diabetes care: comparing specialist with generalist care misses the pointBaiju R Shah, Janet E Hux, Andreas Laupacis, et al.
Diabetes Care|December 17, 2009
Effect of Rosiglitazone and Ramipril on {beta}-cell function in people with impaired glucose tolerance or impaired fasting glucose: the DREAM trialAnthony J Hanley, Bernard Zinman, Patrick Sheridan, et al.
Diabetes Care|June 29, 2011
Changes over time in glycemic control, insulin sensitivity, and beta-cell function in response to low-dose metformin and thiazolidinedione combination therapy in patients with impaired glucose toleranceRavi Retnakaran, Ying Qi, Stewart B Harris, et al.
Diabetes Care|November 25, 2003
Adiponectin in a native Canadian population experiencing rapid epidemiological transitionAnthony J G Hanley, Philip W Connelly, Stewart B Harris, et al.
The Journal of Clinical Endocrinology and Metabolism|August 1, 2015
The Impact of Chronic Liraglutide Therapy on Glucagon Secretion in Type 2 Diabetes: Insight From the LIBRA TrialCaroline K Kramer, Bernard Zinman, Haysook Choi, et al.
Diabetes, Obesity & Metabolism|February 10, 2017
Chronic liraglutide therapy induces an enhanced endogenous glucagon-like peptide-1 secretory response in early type 2 diabetesCaroline K Kramer, Bernard Zinman, Haysook Choi, et al.
The Journal of Clinical Endocrinology and Metabolism|May 5, 2017
Impact of the Glucagon Assay When Assessing the Effect of Chronic Liraglutide Therapy on Glucagon SecretionCaroline K Kramer, Bernard Zinman, Haysook Choi, et al.
Diabetes, Obesity & Metabolism|September 18, 2025
Empagliflozin for the preservation of beta-cell function in women with recent gestational diabetes: A randomized placebo-controlled trialShamini Murugavel, Ravi Retnakaran, Denice S Feig, et al.
Endocrine Practice : Official Journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists|June 7, 2019
INTERMITTENT INTENSIVE INSULIN THERAPY FOR TYPE 2 DIABETES: EFFECTS ON HYPOGLYCEMIA, WEIGHT GAIN, AND QUALITY OF LIFE OVER 2 YEARSAlexandra Emery, Chang Ye, Haysook Choi, et al.
The American Journal of Medicine|July 9, 2010
Confronting the type 2 diabetes epidemic: the emerging role of incretin-based therapiesVivian A Fonseca, Bernard Zinman, Michael A Nauck, et al.
Pageof 40